blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2368914

EP2368914 - Anti-5T4 antibodies and uses thereof [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  10.07.2020
Database last updated on 24.04.2024
FormerThe patent has been granted
Status updated on  30.11.2018
FormerGrant of patent is intended
Status updated on  14.09.2018
FormerExamination is in progress
Status updated on  03.09.2018
FormerGrant of patent is intended
Status updated on  22.04.2018
FormerExamination is in progress
Status updated on  07.06.2017
FormerGrant of patent is intended
Status updated on  16.05.2017
FormerExamination is in progress
Status updated on  03.01.2017
Most recent event   Tooltip12.04.2024Lapse of the patent in a contracting state
New state(s): CY		published on 15.05.2024 [2024/20]
Applicant(s)For all designated states
Wyeth LLC
235 East 42nd Street
New York, NY 10017-5755 / US
[2014/10]
Former [2011/39]For all designated states
Wyeth LLC
Five Giralda Farms
Madison, NJ 07940 / US
Inventor(s)01 / Boghaert, Erwin, R.
93 Ludlam Road
Monroe, NY 10950 / US
02 / Damle, Nitin, K.
53 Stevenson Lane
Upper Saddle River, NJ 07458 / US
03 / Hamann, Philip, Ross
9 Jacobs Road
Thiells, NY 10984 / US
04 / Khandke, Kiran
120 Eant Allison Avenue
Nanuet, NY 10954 / US
05 / Kunz, Arthur
11 Jennifer Drive
New City, NY 10956 / US
06 / Marquette, Kimberly, A.
66 Springfield Street Apt. 1
Somerville, MA 02143 / US
07 / Tchistiakova, Lioudmile
19 Abbot Bridge Drive
Andover, MA 01810 / US
08 / Gill, Davinder
20 Charlotte Drive
Andover, MA 01810 / US
09 / Sreekumar, Kodangattil, Raman
140 Parker Road
Plainsboro, NJ 08536 / US
 [2011/39]
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2012/33]
Former [2011/39]Porter, Jonathan Philip
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date11154157.909.03.2007
[2011/39]
Priority number, dateUS20060781346P10.03.2006         Original published format: US 781346 P
US20070891248P23.02.2007         Original published format: US 891248 P
[2011/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2368914
Date:28.09.2011
Language:EN
[2011/39]
Type: B1 Patent specification 
No.:EP2368914
Date:02.01.2019
Language:EN
[2019/01]
Search report(s)(Supplementary) European search report - dispatched on:EP10.08.2011
ClassificationIPC:C07K16/30, A61K39/395, C07K14/47
[2011/39]
CPC:
A61P35/00 (EP,US); C07K16/00 (KR); C07K16/30 (EP,US);
A61K39/395 (KR); A61K47/6849 (EP,US); A61K51/1027 (US);
C07K14/47 (KR); C07K14/82 (US); C07K16/28 (US);
C07K16/32 (US); A61K2039/505 (EP,US); C07K2317/24 (EP,US);
C07K2317/33 (US); C07K2317/34 (EP,US); C07K2317/52 (US);
C07K2317/56 (EP,US); C07K2317/565 (EP,US); C07K2317/77 (US);
C07K2317/92 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/01]
Former [2011/39]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Antikörper gegen 5T4 und Anwendungen davon[2011/39]
English:Anti-5T4 antibodies and uses thereof[2011/39]
French:Anticorps anti-5T4 et leurs utilisations[2011/39]
Examination procedure11.02.2011Examination requested  [2011/39]
06.09.2011Despatch of a communication from the examining division (Time limit: M06)
16.03.2012Reply to a communication from the examining division
02.05.2013Despatch of a communication from the examining division (Time limit: M06)
12.11.2013Reply to a communication from the examining division
05.02.2015Despatch of a communication from the examining division (Time limit: M04)
15.07.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
23.09.2015Reply to a communication from the examining division
21.07.2016Communication of intention to grant the patent
22.08.2016Observations by third parties
14.10.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.10.2016Despatch of a communication from the examining division (Time limit: M04)
24.02.2017Reply to a communication from the examining division
17.05.2017Communication of intention to grant the patent
22.05.2017Observations by third parties
07.06.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.06.2017Despatch of a communication from the examining division (Time limit: M06)
15.12.2017Reply to a communication from the examining division
07.02.2018Observations by third parties
23.04.2018Communication of intention to grant the patent
30.08.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.08.2018Fee for grant paid
30.08.2018Fee for publishing/printing paid
13.09.2018Information about intention to grant a patent
13.09.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07758256.7  / EP1994055
Divisional application(s)EP18213944.4  / EP3539989
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070758256) is  12.02.2009
Opposition(s)Opponent(s)01  01.10.2019    ADMISSIBLE
Synthon Biopharmaceuticals B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
't Hoen-van der Hoogt, Cornelia Catharina, et al, et al
Byondis B.V.
Microweg 22
6545 CM Nijmegen / NL
 [N/P]
Former [2019/45]
Opponent(s)01  01.10.2019    ADMISSIBLE
Synthon Biopharmaceuticals B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
't Hoen-van der Hoogt, Cornelia Catharina, et al, et al
Synthon Biopharmaceuticals B.V.
IP Research
P.O. BOX 7071
6503 GN Nijmegen / NL
15.10.2019Invitation to proprietor to file observations on the notice of opposition
29.01.2020Reply of patent proprietor to notice(s) of opposition
04.02.2020Despatch of communication that the patent will be revoked
14.02.2020Legal effect of revocation of patent [2020/33]
Request for further processing for:23.09.2015Request for further processing filed
23.09.2015Full payment received (date of receipt of payment)
Request granted
06.10.2015Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
23.09.2015Request for further processing filed
23.09.2015Full payment received (date of receipt of payment)
Request granted
06.10.2015Decision despatched
Fees paidRenewal fee
14.06.2011Renewal fee patent year 03
14.06.2011Renewal fee patent year 04
14.06.2011Renewal fee patent year 05
31.03.2012Renewal fee patent year 06
02.04.2013Renewal fee patent year 07
31.03.2014Renewal fee patent year 08
31.03.2015Renewal fee patent year 09
31.03.2016Renewal fee patent year 10
31.03.2017Renewal fee patent year 11
03.04.2018Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.03.2007
AT02.01.2019
CY02.01.2019
CZ02.01.2019
EE02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
RO02.01.2019
SI02.01.2019
SK02.01.2019
LU09.03.2019
MT09.03.2019
CH31.03.2019
LI31.03.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
[2024/20]
Former [2021/32]HU09.03.2007
AT02.01.2019
CZ02.01.2019
EE02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
RO02.01.2019
SI02.01.2019
SK02.01.2019
LU09.03.2019
MT09.03.2019
CH31.03.2019
LI31.03.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2020/29]AT02.01.2019
CZ02.01.2019
EE02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
RO02.01.2019
SI02.01.2019
SK02.01.2019
LU09.03.2019
MT09.03.2019
CH31.03.2019
LI31.03.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2020/11]AT02.01.2019
CZ02.01.2019
EE02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
RO02.01.2019
SI02.01.2019
SK02.01.2019
LU09.03.2019
CH31.03.2019
LI31.03.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2020/01]AT02.01.2019
CZ02.01.2019
EE02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
RO02.01.2019
SK02.01.2019
LU09.03.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/49]AT02.01.2019
CZ02.01.2019
EE02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
RO02.01.2019
SK02.01.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/46]AT02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
PL02.01.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/39]LT02.01.2019
LV02.01.2019
PL02.01.2019
BG02.04.2019
GR03.04.2019
IS02.05.2019
PT02.05.2019
Former [2019/38]LT02.01.2019
PL02.01.2019
BG02.04.2019
GR03.04.2019
PT02.05.2019
Former [2019/37]LT02.01.2019
PL02.01.2019
GR03.04.2019
PT02.05.2019
Former [2019/35]LT02.01.2019
PL02.01.2019
PT02.05.2019
Former [2019/33]LT02.01.2019
PT02.05.2019
Documents cited:Search[I]WO03038098  (OXFORD BIOMEDICA LTD [GB], et al) [I] 1-16 * page 2, line 11 - page 9, line 4 * * example -; claim - *;
 [IP]WO2006031653  (WYETH CORP [US], et al) [IP] 1-16 * page 1, line 7 - line 11 * * page 4, line 10 - line 26 ** example -; claim - *;
 [IP]WO2006042158  (WYETH CORP [US], et al) [IP] 1-16 * page 1, line 35 - page 2, line 17 * * page 8, line 9 - line 17 * * page 18, line 16 - page 29, line 25 * * page 25, line 26 - page 26, line 16 * * example 3; claim - *;
 [I]  - MYERS K A ET AL, "TARGETING IMMUNE EFFECTOR MOLECULES TO HUMAN TUMOR CELLS THROUGH GENETIC DELIVERY OF 5T4-SPECIFIC SCFV FUSION PROTEINS", CANCER GENE THERAPY, NORWALK, CT, US, (200211), vol. 9, no. 11, ISSN 0929-1903, pages 884 - 896, XP009007160 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.cgt.7700513
 [I]  - FORSBERG G ET AL, "THERAPY OF HUMAN NON-SMALL-CELL LUNG CARCINOMA USING ANTIBODY TARGETING OF A MODIFIED SUPERANTIGEN", BRITISH JOURNAL OF CANCER, LONDON, GB, (20010706), vol. 85, no. 1, ISSN 0007-0920, pages 129 - 136, XP001145660 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1054/bjoc.2001.1891
 [I]  - SHAW A D M ET AL, "Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4", BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, (20001215), vol. 1524, no. 2-3, ISSN 0304-4165, pages 238 - 246, XP004275928 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0304-4165(00)00165-3
 [I]  - SHAW DAVID M ET AL, "Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, (20020401), vol. 363, no. 1, ISSN 0264-6021, pages 137 - 145, XP002444306 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1042/0264-6021:3630137
 [I]  - FORSBERG G\RAN ET AL, "Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, (19970509), vol. 272, no. 19, doi:10.1074/JBC.272.19.12430, ISSN 0021-9258, pages 12430 - 12436, XP002389356 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.272.19.12430
 [I]  - HOLE N ET AL, "A 72KD TROPHOBLAST GLYCOPROTEIN DEFINED BY A MONOCLONAL ANTIBODY", BRITISH JOURNAL OF CANCER, (1988), vol. 57, no. 3, ISSN 0007-0920, pages 239 - 246, XP002653671 [I] 1-16 * the whole document *
 [I]  - HOLE N ET AL, "ISOLATION AND CHARACTERIZATION OF 5T4 A TUMOR-ASSOCIATED ANTIGEN", INTERNATIONAL JOURNAL OF CANCER, (1990), vol. 45, no. 1, ISSN 0020-7136, pages 179 - 184, XP002653672 [I] 1-16 * the whole document *
 [A]  - MYERS K A ET AL, "ISOLATION OF A CDNA ENCODING 5T4 ONCOFETAL TROPHOBLAST GLYCOPROTEIN", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (19940325), vol. 269, no. 12, ISSN 0021-9258, pages 9319 - 9324, XP002064468 [A] 1-16 * abstract *
 [A]  - WOODS ANDREW M ET AL, "Characterization of the murine 5T4 oncofoetal antigen: A target for immunotherapy in cancer", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, (20020815), vol. 366, no. 1, ISSN 0264-6021, pages 353 - 365, XP002341798 [A] 1-16 * abstract *
by applicantUS4196265
 US4671958
 WO8907947
 US4946778
 US4970198
 WO9109967
 US5037651
 US5053394
 US5079233
 US5091513
 US5108912
 US5132405
 US5260203
 US5606040
 US5648095
 US5677427
 US5712374
 US5714586
 US5739277
 US5739116
 US5770710
 US5773001
 WO9855607
 US5869053
 US5877296
 US5892019
 US5952329
 US5985279
 US6024938
 US6054561
 US6309633
 US6310185
 EP1152060
 EP1160323
 GB2370571
 US6461603
 WO02096948
 US2002197262
 US2003018004
 US2003017534
 US2003032995
 GB2378704
 US2003040606
 US2004082764
 US2006002942
 WO2006031653
    - REFF ET AL., CANCER CONTROL, (2002), vol. 9, pages 152 - 66
    - SIEVERS, CANCER CHEMOTHER. PHARMACOL., (2000), vol. 46, pages 18 - 22
    - GOLDENBERG, CRIT. REV. ONCOL. HEMATOL., (2001), vol. 39, pages 195 - 201
    - SIEVERS ET AL., BLOOD, (1999), vol. 93, pages 3678 - 84
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 5
    - QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 33
    - NEWMAN ET AL., BIOTECHNOLOGY, (1992), vol. 10, pages 1455 - 60
    - GREEN ET AL., NAT. GENET., (1994), vol. 7, pages 13 - 21
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 97
    - MAGDELENAT, J. IMMUNOL. METHODS, (1992), vol. 150, pages 133 - 43
    - HOLE ET AL., BR. J. CANCER, (1988), vol. 57, pages 239 - 46
    - HOLE ET AL., INT. J. CANCER, (1990), vol. 45, pages 179 - 84
    - MYERS ET AL., J. BIOL. CHEM., (1994), vol. 269, pages 9319 - 24
    - SOUTHALL ET AL., BR. J. CANCER, (1990), vol. 61, pages 89 - 95
    - MIEKE ET AL., CLIN. CANCER RES., (1997), vol. 3, pages 1923 - 1930
    - STARZYNSKA ET AL., BR. J. CANCER, (1994), vol. 69, pages 899 - 902
    - STARZYNSKA ET AL., BR. J. CANCER, (1992), vol. 66, pages 867 - 869
    - JONES ET AL., BR. J. CANCER, (1990), vol. 61, pages 96 - 100
    - CONNOR; STERN, INT. J. CANCER, vol. 46, pages 1029 - 1034
    - ALI ET AL., ORAL ONCOLOGY, (2001), vol. 37, pages 57 - 64
    - MULDER ET AL., CLIN. CANCER RES., (1997), vol. 3, pages 1923 - 30
    - NAGANUMA ET AL., ANTICANCER RES., (2002), vol. 22, pages 1033 - 1038
    - STARZYNSKA ET AL., EUR. J. GASTROENTEROL. HEPATOL., (1998), vol. 10, pages 479 - 484
    - WRIGLEY ET AL., INT. J. GYNECOL. CANCER, (1995), vol. 5, pages 269 - 274
    - SHAW ET AL., BIOCHEM. J., (2002), vol. 363, pages 137 - 45
    - WOODS ET AL., BIOCHEM. J., (2002), vol. 366, pages 353 - 65
    - MYERS ET AL., CANCER GENE THER., (2002), vol. 9, pages 884 - 896
    - SHAW ET AL., BIOCHIM. BIOPHYS. ACTA, (2000), vol. 1524, pages 238 - 246
    - FORSBERG ET AL., J. CANCER, (2001), vol. 85, pages 129 - 136
    - CHENG ET AL., J. CLIN. ONCOL., (2004), vol. 22, no. 4, pages 602 - 9
    - MULRYAN ET AL., MOL. CANCER THER., (2002), vol. 1, pages 1129 - 37
    - MYERS ET AL., J. BIOL. CHEM., (1994), vol. 269, no. 12, pages 9319 - 9324
    - HOLE ET AL., INT. J. CANCER, (1990), vol. 45, pages 179 - 184
    - BENINCOSA ET AL., J. PHARMACOL. EXP. THER., (2000), vol. 292, pages 810 - 6
    - KALOFONOS ET AL., EUR. J. CANCER, (1994), vol. 30A, pages 1842 - 50
    - SUBRAMANIAN ET AL., PEDIATR. INFECT. DIS. J., (1998), vol. 17, pages 110 - 5
    - MARTIN ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 9268 - 9272
    - MARTIN ET AL., METHODS ENZYMOL., (1991), vol. 203, pages 121 - 153
    - PEDERSEN ET AL., IMMUNOMETHODS, (1992), vol. 1, page 126
    - REES ET AL., Protein Structure Prediction, OXFORD UNIVERSITY PRESS, (1996), pages 141 - 172
    - PADLAN ET AL., FASEB J., (1995), vol. 9, pages 133 - 139
    - PADLAN, MOL. IMMUNOL., (1991), vol. 28, pages 489 - 98
    - PADLAN ET AL., FASEB J., (1995), vol. 9, pages 133 - 9
    - FORSBERG ET AL., J. BIOL. CHEM., (1997), vol. 272, no. 19, pages 124430 - 12436
    - WOLFF ET AL., CANCER RES., (1993), vol. 53, pages 2560 - 5
    - STEVENSON ET AL., ANTICANCER DRUG DES., (1989), vol. 3, pages 219 - 30
    - ANGAL ET AL., MOL. IMMUNOL., (1993), vol. 30, pages 105 - 108
    - YANG ET AL., J. MOL. BIOL., (1995), vol. 254, pages 392 - 403
    - MARKS ET AL., BIOTECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - LOW ET AL., J. MOL. BIOL., (1996), vol. 260, pages 359 - 368
    - PATTEN ET AL., CURR. OPIN. BIOTECHNOL., (1997), vol. 8, pages 724 - 733
    - THOMPSON ET AL., J. MOL. BIOL., (1996), vol. 256, pages 77 - 88
    - CRAMERI ET AL., NATURE, (1998), vol. 391, pages 288 - 291
    - POTTER ET AL., INT. REV. IMMUNOL., (1993), vol. 10, no. 2-3, pages 103 - 112
    - HOUDEBINE, CURR. OPIN. BIOTECHNOL., (2002), vol. 13, no. 6, pages 625 - 629
    - SCHILLBERG ET AL., CELL MOL. LIFE SCI., (2003), vol. 60, no. 3, pages 433 - 45
    - TIJSSEN, Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, ELSEVIER
    - BATZER ET AL., NUCLEIC ACIDS RES., (1991), vol. 19, page 5081
    - OHTSUKA ET AL., J. BIOL. CHEM., (1985), vol. 260, pages 2605 - 2608
    - ROSSOLINI ET AL., MOL. CELL PROBES, (1994), vol. 8, pages 91 - 98
    - SMITH; WATERMAN, ADV. APPL. MATH, (1981), vol. 2, pages 482 - 489
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 443 - 453
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 2444 - 2448
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - BAKKER ET AL., J. NUCL. MED., (1990), vol. 31, pages 1501 - 1509
    - CHATTOPADHYAY ET AL., NUCL. MED. BIOL., (2001), vol. 28, pages 741 - 744
    - DEWANJEE ET AL., J. NUCL. MED., (1994), vol. 35, pages 1054 - 63
    - KRENNING ET AL., LANCET, (1989), vol. 1, pages 242 - 244
    - SAGIUCHI ET AL., ANN. NUCL. MED., (2001), vol. 15, pages 267 - 270
    - YOO ET AL., J. NUCL. MED., (1997), vol. 38, pages 294 - 300
    - KRENNING ET AL., LANCET, (1989), vol. 1, pages 242 - 4
    - BAKKER ET AL., J. NUCL. MED., (1990), vol. 31, pages 1501 - 9
    - JONES ET AL., J. IMMUNOL. METHODS, (2001), vol. 254, pages 85 - 98
    - HOVES ET AL., METHODS, (2003), vol. 31, pages 127 - 34
    - PENG ET AL., CHIN. MED. SCI. J., (2002), vol. 17, pages 17 - 21
    - YASUHARA ET AL., J. HISTOCHEM. CYTOCHEM., (2003), vol. 51, pages 873 - 885
    - BOGHAERT ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 4538 - 4549
    - ONN ET AL., CLIN. CANCER RES., (2003), vol. 9, no. 15, pages 5532 - 5539
    - YUHAS ET AL., CANCER RES., (1977), vol. 37, pages 3639 - 3643
 US20030699874
otherWO2007106744
 EP1994055
    - SHAW DAVID M. ET AL, "Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen", Biochem. J., vol. 363, no. 1, (20020400), pages 137 - 145, XP002444306

DOI:   http://dx.doi.org/10.1042/0264-6021:3630137
OppositionWO03038098
 WO2006031653
 WO2011133039
 WO2012131527
    - Sapra et al., "Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells", Molecular Cancer Therapeutics, (201301), vol. 12, no. 1, pages 38 - 47, XP055197709

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-12-0603
    - BOQHAERT et al., "The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin", Int. J. Oncol., (20080000), vol. 32, pages 221 - 234, XP055051976

DOI:   http://dx.doi.org/10.3892/ijo.32.1.221
    - Doronina et al., "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity", Bioconjugate Chemistry, (2006), vol. 17, pages 114 - 124, XP055009264

DOI:   http://dx.doi.org/10.1021/bc0502917
    - SHAW et al., "Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen", Biochem. J., (20020000), vol. 363, pages 137 - 145, XP002444306

DOI:   http://dx.doi.org/10.1042/0264-6021:3630137
    - MYERS et al., "TARGETING IMMUNE EFFECTOR MOLECULES TO HUMAN TUMOR CELLS THROUGH GENETIC DELIVERY OF 5T4-SPECIFIC SCFV FUSION PROTEINS", Cancer Gene Therapy, (20020000), vol. 9, pages 884 - 896, XP009007160

DOI:   http://dx.doi.org/10.1038/sj.cgt.7700513
    - FORSBERG et al., "Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli", J. Biol. Chem., (19970000), vol. 272, no. 19, pages 12430 - 12436, XP002389356

DOI:   http://dx.doi.org/10.1074/jbc.272.19.12430
    - FORSBERQ et al., "THERAPY OF HUMAN NON-SMALL-CELL LUNG CARCINOMA USING ANTIBODY TARGETING OF A MODIFIED SUPERANTIGEN", Br. J Cancer, (20010000), vol. 85, no. 1, pages 129 - 136, XP001145660

DOI:   http://dx.doi.org/10.1054/bjoc.2001.1891
    - SHAW et al., "Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4", Biochem. Biophys. Acta, (20000000), vol. 1524, pages 238 - 246, XP004275928

DOI:   http://dx.doi.org/10.1016/S0304-4165(00)00165-3
    - "Chapter 1.9 - Routine Manufacture of MAbs", Jörg Knäblein, Modern Biopharmaceuticals, vol. 3, pages 1127 - 1132, XP055646597
    - Jain et al., "Current ADC Linker Chemistry", Pharmaceutical Research, (2015), vol. 32, pages 3526 - 3540, XP035553874

DOI:   http://dx.doi.org/10.1007/s11095-015-1657-7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.